0 results available. Select is focused ,type to refine list, press Down to open the menu,
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United ...
The following section summarizes insights on Harmony Biosciences Holdings's Stock-Based Comp, SG&A Expense:
We've identified the following companies as similar to Harmony Biosciences Holdings because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Stock-Based Comp, SG&A Expense in the financials category include:
Harmony Biosciences did not report meaningful stock-based comp, sg&a expense for the latest twelve months ending December 31, 2024 on its income statement.
The tables below summarizes Harmony Biosciences’s Stock-Based Comp, SG&A Expense and common size over the last five years:
| Fiscal Year | Stock-Based Comp, SG&A Expense | Revenue | % Revenue |
|---|---|---|---|
| 2020-12-31 | NA | 159.7 M | 0.0% |
| 2021-12-31 | NA | 305.4 M | 0.0% |
| 2022-12-31 | NA | 437.9 M | 0.0% |
| 2023-12-31 | NA | 582 M | 0.0% |
| 2024-12-31 | NA | 714.7 M | 0.0% |
The tables below summarizes Harmony Biosciences’s Stock-Based Comp, SG&A Expense and common size over the last four quarters:
| Quarter Ending | Stock-Based Comp, SG&A Expense | Revenue | % Revenue |
|---|---|---|---|
| 2024-03-31 | NA | 154.6 M | 0.0% |
| 2024-06-30 | NA | 172.8 M | 0.0% |
| 2024-09-30 | NA | 186 M | 0.0% |
| 2024-12-31 | NA | 201.3 M | 0.0% |
The chart above depicts the distribution of stock-based comp, sg&a expense for companies operating in the Healthcare sector in the Developed economic region. Over 400 companies were considered in this analysis, and 393 had meaningful values. The average stock-based comp, sg&a expense of companies in the sector is 24.774 M with a standard deviation of 45.552 M.
Harmony Biosciences Holdings's Stock-Based Comp, SG&A Expense of - ranks in the - percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 407 |
| Included Constituents | 393 |
| Min | -356.837 K |
| Max | 288 M |
| Median | 6.551 M |
| Mean | 24.774 M |
| Standard Deviation | 45.552 M |
You can find companies with similar stock-based comp, sg&a expense using this stock screener.